| Bioactivity | PF-07059013 is an orally active and potent noncovalent modulator of sickled hemoglobin (HbS). PF-07059013 specifically binds to Hb with nanomolar affinity and displays strong partitioning into red blood cells (RBCs). PF-07059013 can be used for sickle cell disease (SCD) research[1][2]. |
| In Vivo | PF-07059013 (10-490 mg/kg，口服灌胃，每日2次，连用2周) 显示 Townes SCD 小鼠的镰刀减少[1]。 Animal Model: |
| Name | PF-07059013 |
| CAS | 2435610-93-6 |
| Formula | C19H16FN5O2 |
| Molar Mass | 365.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gopalsamy A, et al. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. J Med Chem. 2021 Jan 14;64(1):326-342. [2]. Aaron Baldwin, et al. Route Optimization of the Non-covalent Modulator of Hemoglobin PF-07059013 for the Treatment of Sickle Cell Disease, Part I: From Discovery Synthesis to First Kilogram-Scale Manufacture. Org. Process Res. Dev. 2023. |